Research into the treatment of mesothelioma is ongoing, although progress has been slow. The latest research (DREAM3R) will be trialed at hospitals around Australia.It uses an immunotherapy drug (Durvalumab) in conjunction with the standard chemotherapy treatment. The hope is that the treatment will lead to an increased survival rate (longer life expectancy – it is not a cure).
Durvalumab is an immunotherapy treatment manufactured by AstraZeneca. It helps the immune system fight cancer.
Candidates for the trial are being recruited from each Australian State. Here in South Australia Flinders Medical Centre is running the trial. If you or anyone you know has an interest in participating, contact your specialist or medical provider for more information.
To learn more about this clinical trial follow these links Cancer Council SA and The Australian New Zealand Clinical Trials Registry (ANZCTR)